In this article by the Canadian Health Policy Institute, readers learn that Canadians wait far longer than patients in the U.S. or Europe to access newly approved medicines. Submission delays, regulatory review, and slower public formulary listing are key barriers. According to the report, these gaps in approval and coverage steps hurt patients who could benefit from earlier access. It also warns that long waits undermine Canada’s competitiveness for clinical trials and investment in life sciences.